22287-32-7

Usage

Uses

Used in Organic Synthesis:
Bicyclo[1.1.1]pentan-1-ylmethanol is used as a building block for the preparation of various organic compounds. Its unique bicyclic structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
Bicyclo[1.1.1]pentan-1-ylmethanol may have potential applications in the pharmaceutical industry due to its unique structure and reactivity. Further research is needed to explore its potential as a starting material for the development of new drugs or as a key intermediate in the synthesis of pharmaceutical compounds.
Used in Agrochemical Industry:
Bicyclo[1.1.1]pentan-1-ylmethanol may also have potential uses in the agrochemical industry. Its unique properties could be harnessed for the development of new agrochemicals or as a building block for the synthesis of existing ones. Further study is required to determine its suitability and potential applications in this field.

Upstream product

• 10555-43-8 1-Brom-3-brommethyl-cyclobutan 
• 35634-10-7 [1.1.1]propellane 
• 117633-03-1 1-bicyclo<1.1.1>pentanecarboxaldehyde 
• 22287-28-1 bicyclo[1.1.1]pentane-1-carboxylic acid 
• 79-37-8 oxalyl dichloride 
• 311-75-1 bicyclo[1.1.1]pentane 

Downstream Products

• 161043-38-5 1-Bromomethylbicyclo<1.1.1>pentane 

Relevant academic research and scientific papers

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Quinuclidine derivative, method for preparing same and application of quinuclidine derivative

The invention relates to a quinuclidine derivative, a pharmaceutically acceptable salt, pro-drug and solvent compound of the quinuclidine derivative, a method for preparing the quinuclidine derivative, a drug composition with the quinuclidine derivative and the pharmaceutically acceptable salt, pro-drug and solvent compound and pharmaceutical application of the quinuclidine derivative. The quinuclidine derivative, the pharmaceutically acceptable salt, pro-drug and solvent compound, the method, the drug composition and the pharmaceutical application have the advantage that the compound is excellent in M3 receptor antagonist activity and accordingly can be used as a novel efficient drug for chronic obstructive pulmonary diseases.

PROPELLANE DERIVATES AND SYNTHESIS

Disclosed herein are compounds of the general Formula (I), and methods of synthesizing substituted bicyclo[1.1.1 jpentanes. The synthetic methods described herein use a [1.1.1]propellane, a Group VIII transition metal compound, a hydride source and a reagent that can contribute a substituent to form a substituted bicycIo[1.1.1 ]pentane, such as a compound of the general Formula (I).

A Kinetic and Theoretical Study of Ring-opening of Bicyclopentylmethyl and Bicyclohexylmethyl Radicals

The rearrangement of the bicyclopentan-1-ylmethyl radical (9) and the bicyclohexan-1-yl-methyl radical (10) to the corresponding methylenecycloalkylmethyl radical (11, 12) has been studied kinetically by EPR spectroscopy and, in the case of